Biomarkers of inflammation and oxidative stress in atherosclerosis

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 361-373

  Uno, Kiyoko ^a   Nicholls, Stephen J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Inflammation; Oxidative stress

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANGIOTENSIN II; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATALASE; CD40 LIGAND; CELL ADHESION MOLECULE; CYTOKINE; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GROWTH FACTOR; HEME OXYGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOREDOXIN;

AGING; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DIABETES MELLITUS; DNA DAMAGE; DYSLIPIDEMIA; ENZYME ACTIVITY; HUMAN; HYPERTENSION; INFLAMMATION; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHEAR STRESS; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 77953799874     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.57     Document Type: Review

References (111)

1. Lloyd-Jones D, Adams R, Carnethon M et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics - 2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 119(3), e21-e181 (2009).
2. Rocha VZ, Libby P: Obesity, inflammation, and atherosclerosis. Nat. Rev. 6(6), 399-409 (2009).
3. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340(2), 115-126 (1999).
4. Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 85(8), 753-766 (1999).
5. Packard RR, Libby P: Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 54(1), 24-38 (2008).
6. Forstermann U: Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. 5(6), 338-349 (2008).
7. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88(6), 1785-1792 (1991).
8. Matsuoka H: Endothelial dysfunction associated with oxidative stress in human. Diabetes Res. Clin. Pract. 54(Suppl. 2), S65-S72 (2001).
9. Siekmeier R, Grammer T, Marz W: Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J. Cardiovasc. Pharmacol. Ther. 13(4), 279-297 (2008).
10. Warnholtz A, Nickenig G, Schulz E et al.: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the rennin-angiotensin system. Circulation 99(15), 2027-2033 (1999).
11. Zalba G, Beloqui O, San Jose G, Moreno MU, Fortuno A, Diez J: NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 25(7), 1452-1457 (2005).
12. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H: Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 91(3A), 7A-11A (2003).
13. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl Acad. USA 76(1), 333-337 (1979).
14. Rizvi AA: Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am. J. Med. Sci. 338(4), 310-318 (2009).
15. Csiszar A, Wang M, Lakatta EG, Ungvari Z: Inflammation and endothelial dysfunction during aging: role of NF-κB. J. Appl. Physiol. 105(4), 1333-1341 (2008).
16. Stary HC, Chandler AB, Glagov S et al.: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89(5), 2462-2478 (1994).
17. Amento EP, Ehsani N, Palmer H, Libby P: Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler. Thromb. 11(5), 1223-1230 (1991).
18. Shah PK: Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol. 41(Suppl. 4), 15S-22S (2003).
19. Hazen SL, Heinecke JW: 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99(9), 2075-2081 (1997).
20. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG: Myeloperoxidase: A useful biomarker for cardiovascular disease risk stratification? Clin. Chem. 55(8), 1462-1470 (2009).
21. Lin HS, Jenner AM, Ong CN, Huang SH, Whiteman M, Halliwell B: A high-throughput and sensitive methodology for the quantification of urinary 8-hydroxy-2́-deoxyguanosine: measurement with gas chromatography-mass spectrometry after single solid-phase extraction. Biochem. J. 380(Pt 2), 541-548 (2004).
22. Morrow JD: Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler. Thromb. Vasc. Biol. 25(2), 279-286 (2005).
23. Stephens JW, Khanolkar MP, Bain SC: The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis 202(2), 321-329 (2009).
24. Tsukahara H: Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr. Med. Chem. 14(3), 339-351 (2007).
25. Yamawaki H, Haendeler J, Berk BC: Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res. 93(11), 1029-1033 (2003).
26. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21(4), 473-480 (2001).
27. Dhamrait SS, Stephens JW, Cooper JA et al.: Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur. Heart J. 25(6), 468-475 (2004).
28. Cave AC, Brewer AC, Narayanapanicker A et al.: NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signal. 8(5-6), 691-728 (2006).
29. Guzik TJ, West NE, Black E et al.: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 86(9), e85-e90 (2000).
30. Fernandes DC, Wosniak J Jr, Pescatore LA et al.: Analysis of DHE-derived oxidation products by HPLC in the assessment of superoxide production and NADPH oxidase activity in vascular systems. Am. J. Physiol. Cell Physiol. 292(1), C413-C422 (2007).
31. Martino F, Loffredo L, Carnevale R et al.: Oxidative stress is associated with arterial dysfunction and enhanced intima-media thickness in children with hypercholesterolemia: the potential role of nicotinamide-adenine dinucleotide phosphate oxidase. Pediatrics 122(3), e648-e655 (2008).
32. Boger RH, Bode-Boger SM, Szuba A et al.: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98(18), 1842-1847 (1998).
33. Boger RH: Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann. Med. 38(2), 126-136 (2006).
34. Tsimikas S: Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr. Atheroscler. Rep. 8(1), 55-61 (2006).
35. Tsimikas S, Witztum JL Miller ER et al.: High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110(11), 1406-1412 (2004).
36. Holvoet P, Mertens A, Verhamme P et al.: Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 21(5), 844-848 (2001).
37. Itabe H, Takeshima E, Iwasaki H et al.: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J. Biol. Chem. 269(21), 15274-15279 (1994).
38. Itabe H, Yamamoto H, Imanaka T et al.: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37(1), 45-53 (1996).
39. Palinski W, Horkko S, Miller E et al.: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98(3), 800-814 (1996).
40. Vejux A, Malvitte L, Lizard G: Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Braz. J. Med. Biol. Res. 41(7), 545-556 (2008).
41. Olkkonen VM, Lehto M: Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis. Ann. Med. 36(8), 562-572 (2004).
42. Bjorkhem I: Are side-chain oxidized oxysterols regulators also in vivo? J. Lipid Res. 50(Suppl.), S213-S218 (2009).
43. Alkazemi D, Egeland G, Vaya J, Meltzer S, Kubow S: Oxysterol as a marker of atherogenic dyslipidemia in adolescence. J Clin. Endocrinol. Metab. 93(11), 4282-4289 (2008).
44. Danesh J, Wheeler JG, Hirschfield GM et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350(14), 1387-1397 (2004).
45. Boekholdt SM, Hack CE, Sandhu MS et al.: C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 187(2), 415-422 (2006).
46. Meuwese MC, Stroes ES, Hazen SL et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk prospective population study. J. Am. Coll. Cardiol. 50(2), 159-165 (2007).
47. Ballantyne CM, Hoogeveen RC, Bang H et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch. Intern. Med. 165(21), 2479-2484 (2005).
48. Danesh J, Kaptoge S, Mann AG et al.: Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 5(4), e78 (2008).
49. Montero I, Orbe J, Varo N et al.: C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J. Am. Coll. Cardiol. 47(7), 1369-1378 (2006).
50. Venugopal SK, Devaraj S, Jialal I: Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr. Opin. Nephrol. Hypertens. 14(1), 33-37 (2005).
51. Scirica BM, Morrow DA: Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113(17), 2128-2134; discussion 2151 (2006).
52. Verma S, Devaraj S, Jialal I: Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 113(17), 2135-2150; discussion 2150 (2006).
53. Lee H, Shi W, Tontonoz P et al.: Role for peroxisome proliferator- activated receptor-a in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ. Res. 87(6), 516-521 (2000).
54. Zhang R, Brennan Ml, Fu X et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286(17), 2136-2142 (2001).
55. Podrez EA, Schmitt D, Hoff HF, Hazen SL: Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103(11), 1547-1560 (1999).
56. Hazen SL, Zhang R, Shen Z et al.: Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation in vivo. Circ. Res. 85(10), 950-958 (1999).
57. Zheng L, Nukuna B, Brennan ML et al.: Apolipoprotein A-1 is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114(4), 529-541 (2004).
58. Caslake MJ, Packard CJ: Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr. Opin. Lipidol. 14(4), 347-352 (2003).
59. Hase M, Tanaka M, Yokota M, Yamada Y: Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat. 70(1-2), 107-118 (2002).
60. Garza CA, Montori VM, Mcconnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F: Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clinic Proc. 82(2), 159-165 (2007).
61. Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ. Res. 89(12), 1092-1103 (2001).
62. Rizvi M, Pathak D, Freedman JE, Chakrabarti S: CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol. Med. 14(12), 530-538 (2008).
63. Koh KK, Han SH, Quon MJ: Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J. Am. Coll. Cardiol. 46(11), 1978-1985 (2005).
64. Koenig W, Khuseyinova N: Biomarkers of atherosclerotic plaque instability and rupture. Arteriosclerosis, Thrombosis, and Vascular Biology 27(1), 15-26 (2007).
65. Galkina E, Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(11), 2292-2301 (2007).
66. Kumar CA, Das UN: Lipid peroxides, anti-oxidants and nitric oxide in patients with pre-eclampsia and essential hypertension. Med. Sci. Monit. 6(5), 901-907 (2000).
67. Turi S, Friedman A, Bereczki C et al.: Oxidative stress in juvenile essential hypertension. J. Hypertens. 21(1), 145-152 (2003).
68. Davi G, Ciabattoni G, Consoli A et al.: In vivo formation of 8-iso-prostaglandin f2a and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99(2), 224-229 (1999).
69. Ceriello A, Quagliaro L, Catone B et al.: Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25(8), 1439-1443 (2002).
70. Martinez-Hervas S, Fandos M, Real JT et al.: Insulin resistance and oxidative stress in familial combined hyperlipidemia. Atherosclerosis 199(2), 384-389 (2008).
71. Furukawa S, Fujita T, Shimabukuro M et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114(12), 1752-1761 (2004).
72. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K: Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 14(6), 561-566 (2003).
73. Holvoet P, Harris TB, Tracy RP et al.: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler. Thromb. Vasc. Biol. 23(8), 1444-1448 (2003).
74. Sigurdardottir V, Fagerberg B, Hulthe J: Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J. Intern. Med. 252(5), 440-447 (2002).
75. Stephens JW, Gable DR, Hurel SJ, Miller GJ, Cooper JA, Humphries SE: Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin. Chem. 52(3), 446-452 (2006).
76. Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G: Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The REYKJAVIK study. J. Cardiovasc. Risk 9(2), 67-76 (2002).
77. Walker M, Whincup PH, Shaper AG: The British Regional Heart study 1975-2004. Int. J. Epidemiol. 33(6), 1185-1192 (2004).
78. Stein JH, Korcarz CE, Hurst RT et al.: Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography carotid intima-media thickness task force. Endorsed by the society for vascular medicine. J. Am. Soc. Echocardiogr. 21(2), 93-111; quiz 189-190 (2008).
79. Glowinska-Olszewska B, Tolwinska J, Urban M: Relationship between endothelial dysfunction, carotid artery intima media thickness and circulating markers of vascular inflammation in obese hypertensive children and adolescents. J. Pediatr. Endocrinol. Metab. 20(10), 1125-1136 (2007).
80. Miyazaki H, Matsuoka H, Cooke JP et al.: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99(9), 1141-1146 (1999). (Pubitemid 29120084)
81. Zoccali C, Benedetto FA, Maas R et al.: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13(2), 490-496 (2002).
82. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K: Endothelial function and oxidative stress in renovascular hypertension. N. Engl. J. Med. 346(25), 1954-1962 (2002).
83. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95(1), 76-82 (1997).
84. Boger RH, Ron ES: l-arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern. Med. Rev. 10(1), 14-23 (2005).
85. Kielstein JT, Impraim B, Simmel S et al.: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109(2), 172-177 (2004). (Pubitemid 38114135)
86. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102(9), 1000-1006 (2000).
87. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95(8), 2068-2074 (1997).
88. Holvoet P, Collen D, Van De Werf F: Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 281(18), 1718-1721 (1999). (Pubitemid 29226482)
89. Toshima S, Hasegawa A, Kurabayashi M et al.: Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20(10), 2243-2247 (2000).
90. Ehara S, Ueda M, Naruko T et al.: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103(15), 1955-1960 (2001).
91. De Lemos JA, Morrow DA, Sabatine MS et al.: Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107(5), 690-695 (2003).
92. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104(3), 365-372 (2001).
93. Nishi K, Itabe H, Uno M et al.: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol. 22(10), 1649-1654 (2002).
94. Anselmi M, Garbin U, Agostoni P et al.: Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis 185(1), 114-120 (2006).
95. Blake GJ, Ostfeld RJ, Yucel EK et al.: Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler. Thromb. Vasc. Biol. 23(1), e11-14 (2003).
96. Heeschen C, Dimmeler S, Hamm CW et al.: Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348(12), 1104-1111 (2003).
97. Hamilton CA, Miller WH, Al-Benna S et al.: Strategies to reduce oxidative stress in cardiovascular disease. Clin. Sci. (Lond.) 106(3), 219-234 (2004).
98. Crawford RS, Kirk EA, Rosenfeld ME, Leboeuf RC, Chait A: Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18(9), 1506-1513 (1998).
99. Davidge ST, Ojimba J, Mclaughlin MK: Vascular function in the vitamin E-deprived rat: an interaction between nitric oxide and superoxide anions. Hypertension 31(3), 830-835 (1998).
100. Gotoh N, Noguchi N, Tsuchiya J et al.: Inhibition of oxidation of low density lipoprotein by vitamin E and related compounds. Free Radic. Res. 24(2), 123-134 (1996). (Pubitemid 26035632)
101. Jialal I, Devaraj S: Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 107(7), 926-928 (2003).
102. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347(9004), 781-786 (1996).
103. de Gaetano G: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative group of the primary prevention project. Lancet 357(9250), 89-95 (2001).
104. Berry C, Anderson N, Kirk AJ, Dominiczak AF, Mcmurray JJ: Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. Heart 86(2), 217-220 (2001).
105. Rueckschloss U, Quinn MT, Holtz J, Morawietz H: Dose-dependent regulation of NAD(P)H oxidase expression by Angiotensin II in human endothelial cells: protective effect of Angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 22(11), 1845-1851 (2002).
106. Ndrepepa G, Braun S, von Beckerath N et al.: Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin. Chim. Acta 360(1-2), 178-186 (2005).
107. Choi SH, Chae A, Miller E et al.: Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal ofAtherosclerosis with Aggressive Lipid Lowering) study. J. Am. Coll. Cardiol. 52(1), 24-32 (2008).
108. Nissen SE, Tuzcu EM, Schoenhagen P et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352(1), 29-38 (2005).
109. Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
110. Pedro-Botet J, Covas MI, Martin S, Rubles-Prat J: Decreased endogenous antioxidant enzymatic status in essential hypertension. J. Hum. Hypertens. 14(6), 343-345 (2000).
111. Schindheim RK, Alssema M, Scheffer PG et al.: Fasting and postprandial glycoxidative and lipoxidative stress are increased in women with Type 2 diabetes. Diabetes Care 30(7), 1789-1794 (2007).